These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28836822)

  • 1. A review of ECG and QT interval measurement use in a public psychiatric inpatient setting.
    Berling I; Gupta R; Bjorksten C; Prior F; Whyte IM; Berry S
    Australas Psychiatry; 2018 Feb; 26(1):50-55. PubMed ID: 28836822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk management of QT-prolonging drugs by community pharmacists using a mobile electrocardiograph].
    Shinozaki K
    Yakugaku Zasshi; 2010 Nov; 130(11):1597-601. PubMed ID: 21048421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged QT Risk Assessment in Antipsychotic Overdose Using the QT Nomogram.
    Berling I; Isbister GK
    Ann Emerg Med; 2015 Aug; 66(2):154-64. PubMed ID: 25639523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug induced QT prolongation].
    Altmann D; Eggmann U; Ammann P
    Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study.
    Girardin FR; Gex-Fabry M; Berney P; Shah D; Gaspoz JM; Dayer P
    Am J Psychiatry; 2013 Dec; 170(12):1468-76. PubMed ID: 24306340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology.
    Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C
    Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulpiride induced torsade de pointes.
    Huang BH; Hsia CP; Chen CY
    Int J Cardiol; 2007 Jun; 118(3):e100-2. PubMed ID: 17408770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lengthening of QT interval by antipsychotic drugs].
    Haverkamp W; Deuschle M
    Nervenarzt; 2006 Mar; 77(3):276, 278-80, 282-4 passim. PubMed ID: 16052325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Psychiatric patients and QT interval monitoring].
    Girardin F; Gaspoz JM
    Rev Med Suisse; 2007 Apr; 3(106):945-8. PubMed ID: 17575970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
    Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
    Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergency department approach to QTc prolongation.
    Pourmand A; Mazer-Amirshahi M; Chistov S; Sabha Y; Vukomanovic D; Almulhim M
    Am J Emerg Med; 2017 Dec; 35(12):1928-1933. PubMed ID: 28855066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement and Management of QT Interval Prolongation for General Physicians.
    Indraratna P; Tardo D; Delves M; Szirt R; Ng B
    J Gen Intern Med; 2020 Mar; 35(3):865-873. PubMed ID: 31654357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Updated Safety Review of the Relationship Between Atypical Antipsychotic Drugs, the QTc Interval and Torsades de Pointe As: Implications for Clinical Use.
    Melo L; Pillai A; Kompella R; Patail H; Aronow WS
    Expert Opin Drug Saf; 2024 Sep; 23(9):1127-1134. PubMed ID: 39126643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long QT syndrome due to olanzapine administration].
    Janion M; Dudek A; Sielski J; Janion-Sadowska A
    Kardiol Pol; 2006 Sep; 64(9):986-8. PubMed ID: 17054030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between atypical antipsychotics drugs, QT interval prolongation, and torsades de pointes: implications for clinical use.
    Ruiz Diaz JC; Frenkel D; Aronow WS
    Expert Opin Drug Saf; 2020 May; 19(5):559-564. PubMed ID: 32189527
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
    Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
    Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antipsychotic drugs and cardiovascular safety: need for monitoring the QT interval].
    Trojak B; Pinoit JM; André D; Bonin B; Gisselmann A
    Presse Med; 2006 Apr; 35(4 Pt 2):699-704. PubMed ID: 16614617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced QT prolongation and sudden death.
    Del Rosario ME; Weachter R; Flaker GC
    Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
    Wolbrette DL
    Curr Cardiol Rep; 2004 Sep; 6(5):379-84. PubMed ID: 15306095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.
    Beach SR; Celano CM; Sugrue AM; Adams C; Ackerman MJ; Noseworthy PA; Huffman JC
    Psychosomatics; 2018; 59(2):105-122. PubMed ID: 29275963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.